Ro centers on FDA-approved brand-name tirzepatide with insurance support; Henry Meds offers lower-cost compounded tirzepatide via async intake. Here's how they compare.
| Ro Body | Henry Meds | |
|---|---|---|
| From / month | $349+/mo | $297/mo |
| Medication type | Brand (Zepbound/Mounjaro) | Compounded tirzepatide |
| FDA status | FDA-approved | Not FDA-approved |
| Clinical oversight | MD-led | Clinician + async intake |
| Pharmacy / fulfillment | Manufacturer / retail | 503A compounding pharmacy |
| Insurance | Prior-auth support | Cash-pay (HSA/FSA) |
Pricing verified as of July 2026 — confirm current figures with each provider. Compounded medications are not FDA-approved.
Ro is MD-led and focuses on brand-name Zepbound/Mounjaro with help navigating insurance prior authorization. Henry Meds uses an asynchronous intake with compounded tirzepatide on the 503A pathway. Eligibility is clinician-determined in both cases.
Ro fulfills through manufacturer/retail pharmacy channels; Henry Meds uses 503A compounding pharmacies. Compounded products are not FDA-approved.
Ro may suit those who want a brand-name product or insurance pathways. Henry Meds may suit cash-pay patients prioritizing low cost and convenience. For a flat-rate compounded alternative with MD/DO oversight, see the NexLife review.
Henry Meds (compounded, ~$297/mo) is generally cheaper cash-pay than Ro (brand, $349+/mo), but Ro's product is FDA-approved and may be insurance-assisted. Compounded tirzepatide is not FDA-approved. See NexLife pricing
Ro dispenses FDA-approved brand-name tirzepatide; Henry Meds dispenses compounded tirzepatide prepared by a 503A pharmacy, which is not FDA-approved.
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.